

ASTRAZENECA PLC

Interim Financial Statements

30 September 2006

Registered number: 2723534



ASTRAZENECA PLC

PROFIT AND LOSS ACCOUNT

for the nine months ended 30 September 2006

| | Notes | 30 September 2006 \$m | 31 December 2005 \$m |
|---|-------|-----------------------------|----------------------------|
| Turnover | | - | - |
| Operating costs | | (6) | (8) |
| Operating loss | | (6) | (8) |
| Income from shares in subsidiary undertakings | | - | 1,183 |
| (Loss)/Profit on ordinary activities before interest | | (6) | 1,175 |
| Net interest and exchange losses | 2 | (5) | (20) |
| (Loss)/Profit on ordinary activities before taxation | | (11) | 1,155 |
| Taxation | | (21) | 113 |
| Net (Loss)/Profit for the year | | (32) | 1,268 |
| Dividends to Shareholders | 3 | (2,217) | (1,676) |
| Loss retained for the year | | (2,249) | (408) |

There are no gains or losses other than those reported above (2005 nil).

ASTRAZENECA PLC

BALANCE SHEET

| | Notes | 30 September 2006 \$m | 31 December 2005 \$m |
|---|-------|-----------------------------|----------------------------|
| Fixed assets | | | |
| Fixed asset investments | 4 | 22,411 | 24,856 |
| Current assets | | | |
| External debtors - other | | 11 | 27 |
| Debtors -- amounts owed by subsidiaries | | 96 | 340 |
| | | 107 | 367 |
| Total assets | | 22,518 | 25,223 |
| Creditors due within one year | | | |
| Short-term borrowings | | (10) | (5) |
| Other creditors | | (35) | (5) |
| Amounts owed to subsidiaries | | (1,543) | (10) |
| | | (1,588) | (20) |
| Net current (liabilities)/assets | | (1,481) | 347 |
| Total assets less current liabilities | | 20,930 | 25,203 |
| Creditors due after more than one year | | | |
| Loans | | (1,030) | (1,030) |
| Net assets | | 19,900 | 24,173 |
| Capital and reserves | | | |
| Called-up share capital | 5 | 388 | 395 |
| Share premium account | 6 | 1,620 | 692 |
| Capital redemption reserve | 6 | 66 | 53 |
| Other reserves | 6 | 1,841 | 1,841 |
| Profit and loss account | 6 | 15,985 | 21,192 |
| Shareholders' funds - equity interests | 7 | 19,900 | 24,173 |

The interim financial statements on pages 1 to 5 were approved by the Board of directors on 25 October 2006 and were signed on its behalf by:



David R Brennan
Director



Jonathan Symonds
Director

ASTRAZENECA PLC

NOTES RELATING TO THE FINANCIAL STATEMENTS

1 Basis of presentation of financial information

The AstraZeneca PLC interim financial statements are presented in accordance with the accounting policies set out in the 2005 annual accounts.

These interim financial statements do not constitute statutory accounts of the Company within the meaning of Section 240 of the Companies Act 1985. Statutory accounts for the year ended 31 December 2005 have been filed with the Registrar of Companies. The auditor's report on those accounts was unqualified and did not contain any statement under Section 237 of the Companies Act 1985.

2 Net interest and exchange losses

| | 30 September 2006 \$m | 31 December 2005 \$m |
|---|-----------------------------|----------------------------|
| Interest payable and similar charges | | |
| Payable to subsidiary undertakings | (17) | (20) |
| External interest payable | (30) | (41) |
| Net exchange losses | (4) | (20) |
| | (51) | (81) |
| Interest receivable and similar income | | |
| Receivable from subsidiary undertakings | 46 | 61 |
| Net interest and exchange losses | (5) | (20) |

NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

3 Dividends to shareholders

| | 30 Sep 2006 Per Share | 31 Dec 2005 Per Share | 30 Sep 2006 \$m | 31 Dec 2005 \$m |
|-------------------------------|-----------------------------|-----------------------------|-----------------------|-----------------------|
| 2 nd interim/final | \$0.92 | \$0.645 | 1,453 | 1,061 |
| 1 st interim | \$0.49 | \$0.38 | 764 | 615 |
| | \$1.41 | \$1.025 | 2,217 | 1,676 |

4 Fixed Asset Investments

| | Shares \$m | Loans \$m | Total \$m |
|-------------------------|---------------|---------------|---------------|
| Cost | | | |
| At beginning of period | 6,715 | 18,141 | 24,856 |
| Repayment of loan | - | (2,445) | (2,445) |
| At end of period | 6,715 | 15,696 | 22,411 |

5 Called-up share capital

| | Authorised | Allotted, called-up and fully paid | |
|--|-----------------------|---------------------------------------|-----------------------|
| | 30 Sep 2006 \$m | 30 Sep 2006 \$m | 31 Dec 2005 \$m |
| Ordinary Shares (\$0.25 each) | 388 | 388 | 395 |
| Unissued Ordinary Shares (\$0.25 each) | 212 | - | - |
| Redeemable Preference Shares (£50,000) | - | - | - |
| | 600 | 388 | 395 |

The movements in share capital during the period can be summarised as follows:

| | No. shares (millions) | \$m |
|-------------------------|--------------------------|------------|
| At beginning of period | 1,581 | 395 |
| Issue of shares | 22 | 6 |
| Repurchase of shares | (52) | (13) |
| At end of period | 1,551 | 388 |

NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

6 Reserves

| | Share Premium Account \$m | Capital Redemption Reserve \$m | Other Reserves \$m | Profit and Loss Account \$m | Total 30 Sep 2006 \$m | Total 31 Dec 2005 \$m |
|---|------------------------------------|---|--------------------------|--------------------------------------|--------------------------------|--------------------------------|
| At beginning of period | 692 | 53 | 1,841 | 21,192 | 23,778 | 27,028 |
| Net (loss)/profit for the period | - | - | - | (32) | (32) | 1,268 |
| Dividends | - | - | - | (2,217) | (2,217) | (1,676) |
| Share repurchase | - | 13 | - | (2,958) | (2,945) | (2,984) |
| Share premiums | 928 | - | - | - | 928 | 142 |
| At end of period | 1,620 | 66 | 1,841 | 15,985 | 19,512 | 23,778 |
| Distributable reserves at end of period | - | - | 1,661 | 1,563 | 3,224 | 5,058 |

At 30 September 2006 \$14,422m (31 December 2005: \$16,867m) of the profit and loss account reserve was not available for distribution. The majority of this non-distributable amount relates to profit arising on the sale of Astra AB to a subsidiary in 1999, which becomes distributable as the underlying receivable is settled in cash. During the nine months \$2,445m of the profit was released by repayment. Subsequent to the period end a further \$3,293m was repaid on 20 October 2006, resulting in additional distributable reserves not included in the figures above. Included in other reserves is a special reserve of \$157m, arising on the redenomination of share capital in 1999.

7 Reconciliation of movements in shareholders' funds

| | 30 September 2006 \$m | 31 December 2005 \$m |
|---|-----------------------------|----------------------------|
| Net (losses)/gains for the financial period | (32) | 1,268 |
| Dividends | (2,217) | (1,676) |
| | (2,249) | (408) |
| Issue of AstraZeneca Ordinary Shares | 934 | 143 |
| Repurchase of AstraZeneca Ordinary Shares | (2,958) | (3,001) |
| Net reduction in shareholders' funds | (4,273) | (3,266) |
| Shareholders' funds at beginning of period | 24,173 | 27,439 |
| Shareholders' funds at end of period | 19,900 | 24,173 |